Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
IL10 / IL10RA mAb | Monospecific antibody | Infectious and parasitic diseases | Immunodeficiencies | PCC | Global |
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
GMP-L10H25 | Human | GMP Human IL-10 Protein |
|
||
CRS-B005 | Human | ClinMax™ Human IL-10 ELISA Kit | |||
IL0-C4248 | Cynomolgus | Cynomolgus IL-10 Protein, His Tag |
|
||
IL0-H5219 | Human | Human IL-10 Protein, premium grade |
|
||
CRS-A008 | Human | resDetect™ Human Interleukin-10 (IL-10) ELISA Kit (Residue Testing) | |||
IL0-M4248 | Mouse | Mouse IL-10 Protein, His Tag |
|
||
IL0-H4248 | Human | Human IL-10 Protein, His Tag |
|
GMP Human IL-10 Protein (Cat. No. GMP-L10H25) inhibits the secretion IL-6 by RAW264.7 cells. The specific activity of GMP Human IL-10 Protein is > 1.00 x 10^7 IU/mg, which is calibrated against WHO Reference Reagent Interleukin-10 (Human, rDNA derived) (NIBSC code: 93/722) (QC tested).
Human IL-10, premium grade (Cat. No. IL0-H5219) inhibits the secrection IL-6 by RAW264.7 cells. The specific activity of Human IL-10, premium grade is >1.00 x 10^7 IU/mg, which is calibrated against WHO Reference Reagent Interleukin-10 (Human, rDNA derived) (NIBSC code: 93/722) (QC tested).
Immobilized Human IL-10, premium grade (Cat. No. IL0-H5219) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-10 R alpha, Fc,Avitag (Cat. No. ILR-H82F6) with a linear range of 0.2-5 ng/mL (QC tested).
The purity of Human IL-10, premium grade (Cat. No. IL0-H5219) is more than 90% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Mesenchymal stem cells therapy (Therapeutic Solutions International) | Phase 3 Clinical | Jadi Cell LLC | Coronavirus Disease 2019 (COVID-19) | Details | |
KLS-2031 | KLS-2031 | Phase 2 Clinical | Kolon Life Science. Inc | Radiculopathy | Details |
WP-1303 (worgpharma) | ATX-MS-1467; ATX-MS-01; M-2736; WP-1303; MSC-2358825A | Phase 2 Clinical | Apitope Technology | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Multiple Myeloma | Details |
XT-150 | XT-101-R; XT-101; XT-150 | Phase 2 Clinical | Xalud Therapeutics Inc | Multiple Sclerosis; Neuralgia; Back Pain; Osteoarthritis, Knee; Arthralgia; Inflammation; Osteoarthritis, Spine | Details |
Mesenchymal stem cells therapy (Therapeutic Solutions International) | Phase 3 Clinical | Jadi Cell LLC | Coronavirus Disease 2019 (COVID-19) | Details | |
KLS-2031 | KLS-2031 | Phase 2 Clinical | Kolon Life Science. Inc | Radiculopathy | Details |
WP-1303 (worgpharma) | ATX-MS-1467; ATX-MS-01; M-2736; WP-1303; MSC-2358825A | Phase 2 Clinical | Apitope Technology | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Multiple Myeloma | Details |
XT-150 | XT-101-R; XT-101; XT-150 | Phase 2 Clinical | Xalud Therapeutics Inc | Multiple Sclerosis; Neuralgia; Back Pain; Osteoarthritis, Knee; Arthralgia; Inflammation; Osteoarthritis, Spine | Details |
This web search service is supported by Google Inc.